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EDITORIAL COMMENT
Atrial Fibrillation—More
Evidence That It’s Here to Stay*
John H. McAnulty, MD, FACC
Portland, Oregon
Wondering how to fit in yet another person with atrial
fibrillation (AF)—given the complexity of decision making
and the time required to appropriately involve patients in
the treatment plans—makes it seem only obvious that the
prevalence of this rhythm must be increasing. In support of
the thought that there “must be more,” is the work by Tsang
et al. (1) published in this issue of the Journal. In this
longitudinal case-control study, the prevalence of a previously
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documented AF was assessed in 1,871 individuals presenting
with an ischemic stroke, and in age- and gender-matched
controls. In both groups, the prevalence increased during each
decade of calendar time from 1960 to 1989, independent of
age, gender, or ischemic stroke status. As with any good work,
this study raises questions. Among these are the following four:
Is it true? In the article by Tsang et al. (1), the authors
acknowledge that “analyzing multiple concurrent trends is a
highly complex process.” Case and control ascertainment
was through assessment of coded diagnoses in a central
diagnostic index. This raises the question of whether coding
approaches, diligence, and interpretation were the same in
the early decade of this trial compared with the last decade.
If it is assumed that the coding was consistent, another
concern is that AF was not considered to be present until
documented on an electrocardiogram. Was the likelihood of
finding the index electrocardiogram the same in all three
time periods? The questions are not enough to doubt the
validity of the findings.
Is it true outside of Rochester, Minnesota? As acknowl-
edged by Tsang et al. (1), the population of Rochester,
Minnesota is predominantly white and, by definition, lives in a
North Midwestern U.S. community. Mr. Garrison Keiller may
well be able to innovatively add to the list of the many obvious
ways this group of individuals differs from those in other parts
of the country and world. As the authors note, cautious
interpretation of the applicability of these findings is appropri-
ate. In support of the observation of an increasing prevalence of
AF is that it is in agreement with findings from other studies
of other, also limited, populations.
Assuming it is true, why? There certainly have been
changes over time in residents having health care contact in
Rochester, Minnesota. Tsang et al. (1) acknowledge that
with their assessment, “cause and effect interpretations are
not possible.” Changes in co-morbidity would seem to be
one obvious explanation. Analysis in this study revealed
increases over time in myocardial infarction and congestive
heart failure in stroke patients and older controls, whereas
diabetes mellitus and coronary bypass surgery increases were
found only in controls. Although this supports the possibil-
ity of an increase in embolic rather than vascular disease as
an explanation for strokes in the later decade, it does not
clearly explain the change in prevalence of AF.
Health care itself may be playing a role. Medications are
always a potential cause of AF, and they certainly have
changed. Additionally, in any age group, individuals are
more likely to survive co-morbid conditions and thus have
the “opportunity” to develop AF.
Any reader can consider his or her own list of potential
explanations, including changes in habits, activity, and
diet. A possible change in the intake of fatty acids is of
interest. Diets rich in long chain polyunsaturated fatty
acids are associated with a decrease in the risk of sudden
cardiac death, and increased trans-fatty acid intake is
associated with an increased risk (2,3). If sudden cardiac
death is most often due to arrhythmias, it could be
hypothesized that a change in intake of these fatty acids
could alter the prevalence of AF as well as ventricular
arrhythmias. There is no definitive evidence for either of
these, although one study has suggested less AF with
increased fish intake (4). The influence of fatty acid
intake is of interest to this writer and his colleagues, but
hypotheses related to other variables could and should be
considered in the same way.
What are the implications of increased AF? The in-
creased morbidity and mortality due to AF are reasons to
look for and correct the likely reasons “why” there is an
increase in this arrhythmia. Until the “why” is better
understood, the increased prevalence is a reason to plan
for the future. If, as Tsang et al. (1) predict, there is a
2.5-fold increase in the prevalence of AF in the next 50
years, attention to management of the prevention of
thromboembolic events will be increasingly important.
We have the chance to optimize anticoagulation man-
agement systems and to better define patient groups who
can be managed with self-monitoring of the International
Normalized Ratio at home. The projections of more AF
should be a stimulus to define alternatives to warfarin or
aspirin and to further define the best anti-fibrillation
therapy for those who will not accept the symptoms of
the rate controlled rhythm.
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